Tool
Stock screener
Filter the 3753 US stocks StockVane tracks, then sort by any column. Results carry the same Quant Rating shown on each stock’s page.
Top Quant-ratedLarge-cap dividend payersCheap & top-ratedBeaten-down (down 20%+ 1yr)High yield (4%+)Mega-cap winners
176 matches
| Company | 60d | Last | Chg% | Mkt cap | P/E | Yield | 1-yr | Quant ↑ |
|---|---|---|---|---|---|---|---|---|
| Aktis OncologyAKTS | 16.15 | -1.52% | $901.14M | -- | -- | -- | D 0 | |
| ApnimedAPMD | 16.09 | -6.70% | $669.84M | 4.13 | -- | -- | C 0 | |
| Attovia TherapeuticsATTO | 15.10 | -3.08% | $690.26M | -- | -- | -- | C 0 | |
| Avalyn PharmaAVLN | 28.40 | -1.05% | $1.26B | -- | -- | -- | C 0 | |
| ELECTRA THERAPEUTICS INCETRA | 8.11 | -9.28% | $509.85M | -- | -- | -- | C 0 | |
| Latigo BiotherapeuticsLTGO | 13.00 | -1.81% | $861.89M | -- | -- | -- | C 0 | |
| Odyssey TherapeuticsODTX | 16.96 | -7.52% | $815.23M | -- | -- | -- | C 0 | |
| SpyGlass PharmaSGP | 30.43 | -1.14% | $1.02B | -- | -- | -- | C 0 | |
| SL ScienceSLBT | 0.55 | -5.37% | $308.42M | -- | -- | -94.8% | E 0 | |
| Seaport TherapeuticsSPTX | 18.05 | -1.47% | $966.23M | -- | -- | -- | C 0 | |
| Theravance Biopharma(Delisted)TBPH | 0.00 | 0.00% | $884.18M | 16.38 | -- | -- | C 0 | |
| First Tracks BiotherapeuticsTRAX | 41.64 | -6.34% | $1.75B | -- | -- | -- | C 0 | |
| Parabilis MedicinesPBLS | 27.44 | -0.67% | $3.44B | -- | -- | -- | C 0 | |
| AtaiBeckleyATAI | 0.00 | 0.00% | $0 | -- | -- | -- | C 0 | |
| Adarx PharmaceuticalsADRX | 12.79 | -9.68% | $1.42B | -- | -- | -- | C 0 | |
| Braveheart BioBRVE | 20.39 | +5.81% | $1.83B | -- | -- | -- | C 0 | |
| Generate BiomedicinesGENB | 9.54 | -8.00% | $1.23B | -- | -- | -- | C 0 | |
| Phathom PharmaceuticalsPHAT | 4.66 | -8.27% | $378.82M | -- | -- | -68.9% | E 2 | |
| Alnylam PharmaceuticalsALNY | 143.82 | -2.71% | $19.26B | 7.48 | -- | -67.0% | E 2 | |
| Mineralys TherapeuticsMLYS | 13.66 | -3.53% | $1.21B | -- | -- | -67.4% | E 2 | |
| Avalo TherapeuticsAVTX | 6.76 | +0.15% | $390.88M | -- | -- | -62.1% | E 3 | |
| Janux TherapeuticsJANX | 10.08 | -2.04% | $616.73M | -- | -- | -65.0% | E 3 | |
| OculisOCS | 7.06 | -5.11% | $437.15M | -- | -- | -63.3% | E 3 | |
| Olema PharmaceuticalsOLMA | 7.02 | -1.82% | $615.00M | -- | -- | -69.7% | E 3 | |
| Ionis PharmaceuticalsIONS | 26.58 | -2.35% | $4.43B | -- | -- | -65.1% | E 3 | |
| Ascentage PharmaAAPG | 11.97 | -3.78% | $1.12B | -- | -- | -60.9% | E 3 | |
| MiMedxMDXG | 3.05 | -1.93% | $445.07M | -- | -- | -54.9% | E 5 | |
| Sana BiotechnologySANA | 1.59 | -8.62% | $476.42M | -- | -- | -51.7% | E 5 | |
| NewAmsterdam PharmaNAMS | 18.41 | -5.64% | $2.21B | -- | -- | -51.9% | E 5 | |
| Structure TherapeuticsGPCR | 16.13 | -5.78% | $1.15B | -- | -- | -53.0% | E 5 | |
| Nektar TherapeuticsNKTR | 30.20 | -7.19% | $1.03B | -- | -- | -44.4% | E 6 | |
| ArdelyxARDX | 2.99 | -2.29% | $751.60M | -- | -- | -44.8% | E 7 | |
| CorMedixCRMD | 5.27 | +3.74% | $419.16M | 8.23 | -- | -45.6% | E 7 | |
| Nuvation BioNUVB | 3.80 | -0.26% | $1.34B | -- | -- | -45.6% | E 7 | |
| Syndax PharmaceuticalsSNDX | 8.72 | -4.49% | $785.05M | -- | -- | -50.0% | E 7 | |
| Ultragenyx PharmaceuticalRARE | 16.48 | -4.30% | $1.68B | -- | -- | -50.9% | E 7 | |
| ArriVent BioPharmaAVBP | 10.52 | -6.57% | $544.13M | -- | -- | -48.3% | E 7 | |
| Bicara TherapeuticsBCAX | 8.44 | -7.46% | $560.31M | -- | -- | -53.2% | E 8 | |
| Gyre TherapeuticsGYRE | 4.21 | -6.86% | $460.79M | -- | -- | -44.2% | E 8 | |
| ImmaticsIMTX | 5.77 | -3.03% | $878.58M | -- | -- | -43.4% | E 8 | |
| Legend BiotechLEGN | 15.25 | -5.28% | $2.96B | -- | -- | -45.9% | E 8 | |
| CelcuityCELC | 53.35 | -5.26% | $2.62B | -- | -- | -45.3% | E 8 | |
| ValnevaVALN | 5.16 | -3.82% | $490.86M | -- | -- | -40.1% | E 9 | |
| AlumisALMS | 3.96 | -8.55% | $514.09M | -- | -- | -45.8% | E 10 | |
| Kura OncologyKURA | 6.91 | -5.99% | $634.88M | -- | -- | -38.1% | E 10 | |
| Summit TherapeuticsSMMT | 9.95 | -5.87% | $7.96B | -- | -- | -38.5% | E 10 | |
| Recursion PharmaceuticalsRXRX | 2.45 | -9.93% | $1.53B | -- | -- | -41.2% | E 10 | |
| Oric PharmaceuticalsORIC | 7.36 | -4.42% | $764.94M | -- | -- | -36.7% | E 11 | |
| RegenxbioRGNX | 7.16 | -0.28% | $473.44M | -- | -- | -39.3% | E 12 | |
| Abivax S.A.ABVX | 73.20 | -9.24% | $6.41B | -- | -- | -38.5% | E 12 | |
| VerastemVSTM | 6.33 | -7.73% | $797.67M | -- | -- | -36.7% | D 14 | |
| InsmedINSM | 141.33 | -2.17% | $31.01B | -- | -- | -28.9% | D 14 | |
| Viking TherapeuticsVKTX | 24.77 | -4.14% | $3.16B | -- | -- | -27.7% | E 14 | |
| ImmunocoreIMCR | 26.41 | -0.83% | $1.36B | -- | -- | -32.9% | E 14 | |
| Pharming GroupPHAR | 11.54 | -5.18% | $816.78M | 34.97 | -- | -29.0% | D 15 | |
| PTC TherapeuticsPTCT | 56.42 | -3.27% | $4.71B | -- | -- | -28.1% | D 17 | |
| ACADIA PharmaceuticalsACAD | 17.11 | -2.73% | $2.96B | 8.07 | -- | -27.4% | D 17 | |
| Dyne TherapeuticsDYN | 15.50 | -3.31% | $2.90B | -- | -- | -26.8% | D 17 | |
| AnnexonANNX | 3.10 | -9.09% | $591.37M | -- | -- | -27.4% | D 18 | |
| InventivaIVA | 3.14 | -8.99% | $750.78M | -- | -- | -27.0% | D 18 |
Reference only, not investment advice. A screen is a starting point, not a buy list. Quant Rating method: Data & Methodology.